F-SLOH
F-SLOH is a brain-penerant and orally active TFEB activator and amyloid-β inhibitor with an IC50 of 3.4 μM against amyloid-β. F-SLOH promotes nuclear translocation of TFEB, driving autophagy and lysosomal biogenesis. F-SLOH reduces amyloid-β oligomers and Tau aggregates via autophagy lysosomal degradation pathway. F-SLOH can be used for the research of Alzheimer’s disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1620896-55-0
- Formule: C30H30ClFN2O3
- Masse moléculaire:521.02
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
F-SLOH potently inhibits Aβ fibril formation in a cell-free biochemical assay with an IC50 of 3.4 μM[1].
F-SLOH (12.5-200 μM) exhibits low cytotoxicity in N2a-APP cells, with significant toxicity only observed at 200 μM[1].
F-SLOH (6.25-50 μM) dose-dependently reduces Aβ1-40 and Aβ1-42 levels in the media of N2a-APP cells[1].
F-SLOH (6.25-25 μM; 24 h) dose-dependently reduces full-length APP and CTFs protein levels in N2a-APP cells after 24 h of treatment[1].
F-SLOH reduces full-length APP levels in N2a-APP cells via a lysosomal degradation pathway[1].
F-SLOH (6.25-25 μM; 24 h) dose-dependently induces TFEB nuclear translocation in cultured microglial cells after 24 h of treatment[1].
F-SLOH (6.25-25 μM; 24 h) dose-dependently induces autophagy in HT-22 cells[1].
F-SLOH (6.25-25 μM; 24 h) dose-dependently promotes lysosomal biogenesis in HT-22 cells after 24 h of treatment[1].
F-SLOH (25 μM; 24 h) promotes autophagy flux and autophagosome-lysosome fusion in HT-22 cells stably expressing tf-LC3[1].
F-SLOH (24 h) increases lysosome number in HT-22 cells[1].
F-SLOH (6.25-25 μM；1-24 小时) inhibits the MAPK1/ERK2 pathway in HT-22 cells in both a dose-dependent and time-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:N2a-APP cells (N2a cells overexpressing APP695)
-
Concentration:6.25 μM; 12.5 μM; 25 μM
-
Incubation Time:24 h
-
Result:Dose-dependently reduced protein levels of full-length APP and its metabolite CTFs.
Caused significant reductions at all tested concentrations relative to control.
-
Cell Line:HT-22 cells
-
Concentration:6.25 μM; 12.5 μM; 25 μM
-
Incubation Time:24 h
-
Result:Dose-dependently increased LC3-II protein levels, indicating induction of autophagy.
Effect was comparable to the positive control Torin1.\nDose-dependently increased protein levels of LAMP1 and mature Cathepsin D, indicating promotion of lysosomal biogenesis.
Effect was comparable to the positive control Torin1.
-
Cell Line:HT-22 cells
-
Concentration:6.25 μM; 12.5 μM; 25 μM
-
Incubation Time:1 h; 2 h; 4 h; 6 h; 8 h; 24 h
-
Result:Dose-dependently reduced phospho-TFEB (S142) levels over 24 h.
Time-dependently reduced phospho-TFEB (S142) levels over 1-8 h.
Increased total TFEB levels, indicating TFEB dephosphorylation.
Dose-dependently reduced phospho-ERK1/2 and phospho-MEK levels over 24 h.
Time-dependently reduced phospho-ERK1/2 and phospho-MEK levels over 0-8 h.
Indicated inhibition of the MAPK1/ERK2 pathway.
| Species | Dose | Route | Cmax | Tmax |
|---|---|---|---|---|
| Mice[1] | 20 mg/kg | i.p. | 81.134 ng/g | 1 h |
F-SLOH (10-20 mg/kg; p.o.; ad libitum; 6 months) dose-dependently reduces Alzheimer's disease pathology, improves cognitive function, and activates TFEB-mediated autophagy-lysosomal pathway in 3XTg-AD mice[1].
F-SLOH (10-20 mg/kg; 1 week) activates TFEB-mediated autophagy-lysosomal pathway in wild-type mice without causing body weight changes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (heterozygous 5XFAD transgenic, 2 months old, male/female)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.p.; alternate days; 4 months
-
Result:Reduced levels of Aβ monomers (Aβ1-40, Aβ1-42), Aβ oligomers, and Aβ plaques in soluble and insoluble brain fractions.
Reduced full-length APP and its CTF metabolites.
Reduced astrocytic activation (GFAP staining) and microgliosis (Iba1 staining).
Increased hippocampal-dependent memory, as shown by prolonged freezing time in contextual fear conditioning tests relative to vehicle-treated mice.
Increased synaptic formation and postsynaptic density protein 95 (PSD-95)/synaptophysin expression.
Activated TFEB, increasing nuclear TFEB translocation, LC3B-II levels, LAMP1 levels, and mature cathepsin D levels to promote autophagy and lysosomal biogenesis.
Increased lysosome and autolysosome formation in hippocampal tissue.
-
Animal Model:B6;129 (female heterozygous 3XTg-AD transgenic, 6-12 months old, N=8 per group)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:p.o.; 6 months
-
Result:Reduced levels of Aβ monomers (Aβ1-40, Aβ1-42), Aβ oligomers, and Aβ plaques in soluble and insoluble brain fractions.
Reduced full-length APP and its CTF metabolites.
Reduced insoluble phosphorylated Tau (AT8, PHF1, CP13, MC1, HT7) levels and AT8/HT7-positive neuron load.
Reduced astrocytic activation (GFAP staining) and microgliosis (Iba1 staining).
Rescued learning impairment (shorter escape latency in Morris water maze), improved spatial memory (increased time spent in target quadrant during probe trial), and increased hippocampal-dependent memory (prolonged freezing time in contextual fear conditioning tests) relative to vehicle-treated mice.
Improved exploratory and locomotor function in open-field tests.
Increased dendritic spine density and postsynaptic density protein 95 (PSD-95)/synaptophysin expression.
Activated TFEB, increasing nuclear TFEB translocation, LC3B-II levels, LAMP1 levels, and mature cathepsin D levels to promote autophagy and lysosomal biogenesis.
-
Animal Model:C57BL/6 (wild-type, N=8 per group)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:1 week
-
Result:Increased nuclear TFEB translocation, reduced cytoplasmic TFEB levels, and increased LC3B-II, LAMP1, and mature cathepsin D levels in brain tissue to promote autophagy and lysosomal biogenesis.
Showed no significant change in mouse body weight.
Chemical Information
-
CAS No. 1620896-55-0
-
Masse moléculaire 521.02
-
Formule C30H30ClFN2O3
-
SMILES
COCCOCCN1C2=CC=C(/C=C/C3=CC=[N+](CCO)C4=C3C=CC=C4)C=C2C5=CC(F)=CC=C51.[Cl-]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
F-SLOH Related Classifications
HY-183660 Related Classifications
Powered by Bioz